SCHEMBL3015401

SCHEMBL3015401

O=S(=O)(c1ccc(Cl)cc1)N1CCN(c2nc(Cc3cccc(Br)c3)cs2)CC1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GBA1 P04062 2/20 0.49
MAPT P10636 4/20 0.46
ALDH1A1 P00352 3/20 0.46
LMNA P02545 2/20 0.46
GAA P10253 2/20 0.46
LSS P48449 2/20 0.45
POLB P06746 1/20 0.45
SMN1; SMN2 Q16637 3/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
USP2 O75604 2/20 0.42
RECQL P46063 1/20 0.42
HSD17B10 Q99714 1/20 0.42
MEN1 O00255 2/20 0.42
KMT2A Q03164 2/20 0.42
NPSR1 Q6W5P4 3/20 0.42
KDM4E B2RXH2 2/20 0.42
RXFP1 Q9HBX9 1/20 0.42
TSHR P16473 1/20 0.41
MAPK1 P28482 1/20 0.41
HTT P42858 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3009030 0.93 CNR1 (0.43) GBA1MAPTALDH1A1LMNAGAA
SCHEMBL3011602 0.93 SMN1; SMN2 (0.46) GBA1MAPTALDH1A1LMNAGAA
SCHEMBL3014383 0.91 MEN1 (0.42) GBA1MAPTALDH1A1SMN1; SMN2L3MBTL1
SCHEMBL3016663 0.91 MEN1 (0.45) GBA1ALDH1A1LMNASMN1; SMN2L3MBTL1
SCHEMBL3018467 0.91 ALDH1A1 (0.43) GBA1MAPTALDH1A1LMNAGAA
SCHEMBL3005969 0.90 GBA1 (0.44) GBA1MAPTALDH1A1LMNAGAA
SCHEMBL3013635 0.90 SMN1; SMN2 (0.44) GBA1MAPTALDH1A1LMNAGAA
SCHEMBL3000011 0.90 ALDH1A1 (0.56) GBA1MAPTALDH1A1LMNAGAA
SCHEMBL3015471 0.90 USP2 (0.44) GBA1MAPTALDH1A1GAASMN1; SMN2
SCHEMBL3012672 0.90 KMT2A (0.50) GBA1MAPTALDH1A1LMNASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA GBA1 4/4885MAPT 18/4885ALDH1A1 3510/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.